-
Mashup Score: 3Zeynep B. Zengin, MD @ZeynepZengin @cityofhope #ASCOGU2 - 2 year(s) ago
Zeynep Busra Zengin, MD, a postdoctoral fellow at the City of Hope, a comprehensive cancer center discusses the ASCO GU 2021 abstract – Illustration of tem
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Advancing Knowledge About The Treatment of Advanced Prostate Cancer, Highlights from GU ASCO 2021 - Praful Ravi - 3 year(s) ago
Praful Ravi, MB, BChir, MRCP, and Alicia Morgans, MD, MPH highlight several prostate cancer abstracts from GU ASCO 2021 and discuss the clinical landscape for treating prostate cancer. They highlight results of the ACIS trial assessing the combination of apalutamide + abiraterone acetate as compared to abiraterone acetate alone in patients with chemo-naive metastatic castration-resistant…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Advancing knowledge about the treatment of advanced #ProstateCancer, highlights from #ASCOGU21. Praful Ravi MB, BChir, MRCP @DanaFarber joins @CaPsurvivorship @NUFeinbergMed discussing the clinical landscape for treating prostate cancer. #WatchNow > https://t.co/qtlTCyGxx6 @ASCO https://t.co/VnVlDyd1DF
-
-
Mashup Score: 0The Treatment Landscape for Advanced Urothelial Carcinoma in 2021 - Jonathan Rosenberg - 3 year(s) ago
Immune checkpoint blockade is a first line therapeutic option in either platinum ineligible patients or carboplatin eligible patients whose tumors also express PD-L1. Patients who are ineligible for cisplatin and progress on immune checkpoint blockade have limited treatment options, and many efforts are underway to expand the therapeutic armamentarium for this disease context. In this…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The treatment landscape for advanced #UrothelialCarcinoma in 2021. @DrRosenbergMSK @sloan_kettering joins @CaPsurvivorship @NUFeinbergMed discussing urothelial carcinoma treatment data presented at the #ASCOGU21 conference. #WatchNow on UroToday > https://t.co/eMT7YPRJYx @ASCO https://t.co/9O201CdIjV
-
-
Mashup Score: 0The Treatment Landscape for Advanced Urothelial Carcinoma in 2021 - Jonathan Rosenberg - 3 year(s) ago
Immune checkpoint blockade is a first line therapeutic option in either platinum ineligible patients or carboplatin eligible patients whose tumors also express PD-L1. Patients who are ineligible for cisplatin and progress on immune checkpoint blockade have limited treatment options, and many efforts are underway to expand the therapeutic armamentarium for this disease context. In this…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The treatment landscape for advanced #UrothelialCarcinoma in 2021. @DrRosenbergMSK @sloan_kettering joins @CaPsurvivorship @NUFeinbergMed discussing urothelial carcinoma treatment data presented at the #ASCOGU21 conference. #WatchNow on UroToday > https://t.co/eMT7YPRJYx @ASCO https://t.co/SbF3zsdt2R
-
-
Mashup Score: 0Advancing Knowledge About The Treatment of Advanced Prostate Cancer, Highlights from GU ASCO 2021 - Praful Ravi - 3 year(s) ago
Praful Ravi, MB, BChir, MRCP, and Alicia Morgans, MD, MPH highlight several prostate cancer abstracts from GU ASCO 2021 and discuss the clinical landscape for treating prostate cancer. They highlight results of the ACIS trial assessing the combination of apalutamide + abiraterone acetate as compared to abiraterone acetate alone in patients with chemo-naive metastatic castration-resistant…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Advancing knowledge about the treatment of advanced #ProstateCancer, highlights from #ASCOGU21. Praful Ravi MB, BChir, MRCP @DanaFarber joins @CaPsurvivorship @NUFeinbergMed discussing the clinical landscape for treating prostate cancer. #WatchNow > https://t.co/qtlTCyY8oE @ASCO https://t.co/5VaCOmrzNe
-
-
Mashup Score: 1The Treatment Landscape for Advanced Urothelial Carcinoma in 2021 - Jonathan Rosenberg - 3 year(s) ago
Immune checkpoint blockade is a first line therapeutic option in either platinum ineligible patients or carboplatin eligible patients whose tumors also express PD-L1. Patients who are ineligible for cisplatin and progress on immune checkpoint blockade have limited treatment options, and many efforts are underway to expand the therapeutic armamentarium for this disease context. In this…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The treatment landscape for advanced #UrothelialCarcinoma in 2021. @DrRosenbergMSK @sloan_kettering joins @CaPsurvivorship @NUFeinbergMed discussing urothelial carcinoma treatment data presented at the #ASCOGU21 conference. #WatchNow on UroToday > https://t.co/eMT7YPRJYx @ASCO https://t.co/knwII0OYwU
-
-
Mashup Score: 0Advancing Knowledge About The Treatment of Advanced Prostate Cancer, Highlights from GU ASCO 2021 - Praful Ravi - 3 year(s) ago
Praful Ravi, MB, BChir, MRCP, and Alicia Morgans, MD, MPH highlight several prostate cancer abstracts from GU ASCO 2021 and discuss the clinical landscape for treating prostate cancer. They highlight results of the ACIS trial assessing the combination of apalutamide + abiraterone acetate as compared to abiraterone acetate alone in patients with chemo-naive metastatic castration-resistant…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Advancing knowledge about the treatment of advanced #ProstateCancer, highlights from #ASCOGU21. Praful Ravi MB, BChir, MRCP @DanaFarber joins @CaPsurvivorship @NUFeinbergMed discussing the clinical landscape for treating prostate cancer. #WatchNow > https://t.co/qtlTCyGxx6 @ASCO https://t.co/V8GHWA741n
-
-
Mashup Score: 2Drug Improves Survival for Rare, Deadly Kidney Cancer - 3 year(s) ago
MONDAY, Feb. 22, 2021 (HealthDay News) — The drug cabozantinib is more effective than two similar drugs, as well as the current standard treatment, in extending the lives of patients with a rare and deadly type of kidney cancer, according to a new study.The cancer is called metastatic papillary kid…
Source: Consumer Health News | HealthDayCategories: Hem/Oncs, Latest HeadlinesTweet-
Thank you @HealthDayEditor @HealthDayMD for sharing. Cabozantinib is more effective than two similar drugs, as well as the current SOC TX, in extending the lives of pts w/ a rare & deadly type of kidney cancer #ASCOGU21 https://t.co/9n97vRuLmx
-
-
Mashup Score: 2
The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.
Source: Cure TodayCategories: Hem/Oncs, Latest HeadlinesTweet-
Cabozantinib significantly prolonged progression-free survival compared to sunitinib in patients with rare form metastatic papillary RCC. @Cure_Today #SWOG1500 #ASCOGU21 https://t.co/xn9yk14FMB
-
-
Mashup Score: 1
The CLEAR trial compared treatment with lenvatinib plus either pembrolizumab or everolimus versus sunitinib in patients with advanced renal cell carcinoma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The CLEAR trial compared treatment with lenvatinib plus either pembrolizumab or everolimus versus sunitinib in patients with advanced renal cell carcinoma. #ASCOGU21 | @sloan_kettering https://t.co/afh5QZPA73
-
Zeynep B. Zengin, MD @ZeynepZengin @cityofhope #ASCOGU21 #Carcinoma #mRCC #Cancer #Research Illustration of temporal evolution in Pts with mRCC using both ctDNA and tissue-based genomic data https://t.co/YKR0t52FiQ https://t.co/5nvq2krpAF